College of Pharmacy
Cicali Lab
Led by Brian Cicali · Pharmaceutics
What we study
The Cicali Lab uses computer models and real-world data to study drug safety and efficacy, focusing on quantitative clinical pharmacology methods. They work with pharmaceutical companies to analyze drug interactions and adverse events.
What working here is like
- Computational
- No organisms (data only)
- Coding required
- Projects
- 2
- Papers
- 5
Current projects
Pharmacology Modeling for Contraceptive Product Development
Using computer models to analyze hormonal contraceptives for efficacy and safety.
Population PK/PD Modeling Analysis of Lomitapide to Evaluate Gastrointestinal Adverse Events
Analyzing drug interactions and side effects in patients taking Lomitapide.
Summaries are written by AI in plain language from public symposium abstracts and may be imperfect.
Recent papers, explained
- Translational Model to Predict Lung and Prostate Distribution of Levofloxacin in Humans
2026 · Pharmaceutics
Built a model to predict levofloxacin's distribution in lung and prostate tissues.
- Explaining clinically important variability in response to simvastatin treatment using a PBPK/PD approach
2026 · The Journal of Clinical Pharmacology
Used a model to study how simvastatin's effects vary in different patients.
Show 3 more papersShow fewer
- Integrating Patient‐Centric Clinical Pharmacology and MID3 to Advance Biologic Development in Immune‐Mediated Inflammatory Diseases
2026 · Clinical Pharmacology & Therapeutics
Developed methods to improve biologic treatments for immune-mediated inflammatory diseases.
- Integrating Static and Dynamic Models to Predict Cannabidiol‐Mediated Metabolic Drug–Drug Interactions
2026 · Clinical Pharmacology & Therapeutics
Used models to predict CBD's potential to cause drug interactions with other medications.
- Bleeding and Thromboembolic Outcomes Following GLP ‐1 Receptor Agonist Initiation in Patients With Type 2 Diabetes and Atrial Fibrillation Receiving Direct Oral Anticoagulants: A Target Trial Emulation
2026 · Diabetes Obesity and Metabolism
Examined bleeding and thromboembolic risks in patients taking GLP-1 agonists and DOACs.
Plain-language summaries are AI-written and reviewed by us; check the paper for details.
How to reach out
Brian Cicali hasn't set up this page yet. Their UF Scholars profile lists their publications.